Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Advances Minimally Invasive Lung Cancer Diagnosis With New Interventional Lung Biopsy System

Executive Summary

With the recent FDA approval of Medtronic's GenCut core biopsy system, the company is moving closer to its vision of diagnosing and treating lung cancer with a completely non-invasive, outpatient solution. GenCut is specifically designed for the unique challenges of lung biopsy/sampling lung lesions and allows physicians to capture larger pieces of lung tissue to be preserved for more in-depth and accurate testing and personalized care when used during bronchoscopy procedures.

Advertisement

Related Content

New Product Briefs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel